Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies

References

• Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–182.
   PubMed Web of Science ®Google Scholar
• Dodick DW. Migraine. Lancet (London, England). 2018;391(10127):1315–1330.
   PubMed Web of Science ®Google Scholar
• Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(2 Suppl):S23–S34.
   PubMed Web of Science ®Google Scholar
• Kahriman A, Zhu S. Migraine and tension-type headache. Semin Neurol. 2018;38(6):608–618.
   PubMed Web of Science ®Google Scholar
• Menon B, Kinnera N. Prevalence and characteristics of migraine in medical students and its impact on their daily activities. Ann Indian Acad Neurol. 2013;16(2):221–225.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Loder E, Forde G, et al. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006;22(6):1021–1029.
   PubMed Web of Science ®Google Scholar
• Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physic. 2018;97(4):243–251.
   PubMed Web of Science ®Google Scholar
• Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–582.
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20.
   PubMed Web of Science ®Google Scholar
• Vargas BB. Acute treatment of migraine. Continuum (Minneap Minn). 2018;24(4, Headache):1032–1051.
   PubMedGoogle Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573–584.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet (London, England). 2008;372(9656):2115–2123.
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–125.
   PubMed Web of Science ®Google Scholar
• Gupta D, Dhaneria S, Singh A. New gepants against acute migraine: a systematic review and network Meta-analysis. Amrita Journal of Medicine. 2021;17(4):109.
   Google Scholar
• Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–898.
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Hutchinson S, et al. Long-Term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-Week extension trial. Headache. 2020;60(1):141–152.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Higgins JG. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated march 2011]. The Cochrane Collaboration. 2011.
   Google Scholar
• Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the jadad scale. Control Clin Trials. 1999;20(5):448–452.
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Higgins JG. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
   Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, Cochrane Statistical Methods Group, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, GRADE Working Group, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898.
   PubMed Web of Science ®Google Scholar
• Jakate A, Blumenfeld AM, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642–652.
   PubMed Web of Science ®Google Scholar
• Singh A, Gupta D, Sahoo AK. Acute migraine: Can the new drugs clinically outpace? SN Compr Clin Med. 2020;2(8):1132–1138.
   Google Scholar
• Yang Y, Chen M, Sun Y, et al. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-Analysis of randomized clinical trials. CNS Drugs. 2020;34(5):463–471.
   PubMed Web of Science ®Google Scholar
• Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.
   PubMedGoogle Scholar
• Goadsby PJ, Tepper SJ, Watkins PB, et al. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019;39(14):1753–1761.
   PubMed Web of Science ®Google Scholar
• Curto M, Capi M, Cipolla F, et al. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother. 2020;21(7):755–759.
   PubMed Web of Science ®Google Scholar